Clozapine Dosing and Monitoring
Start clozapine at 12.5 mg once or twice daily, titrate slowly to minimize cardiovascular and inflammatory risks, target maintenance doses of 300-600 mg/day (or lower based on ancestry and metabolism), and aim for plasma levels of 350-550 ng/mL for optimal response. 1
Starting Dose and Initial Titration
Begin with 12.5 mg once or twice daily to minimize the risk of orthostatic hypotension, bradycardia, syncope, and cardiac arrest, which are highest during initial titration and can occur even with the first dose. 1
Standard Titration Approach
- Titrate gradually using divided dosing to reduce dose-related risks of seizures, cardiovascular events, and inflammatory complications. 1
- The FDA label emphasizes slow titration with divided doses but does not specify exact increments beyond the 12.5 mg starting dose. 1
- Avoid rapid dose escalation, as this substantially increases risk of myocarditis, pneumonia, and orthostatic hypotension during the first 3-4 weeks. 2, 3
Ancestry-Based Personalized Titration
Consider slower titration schedules based on ancestry and metabolic factors, as clozapine metabolism varies significantly across populations:
- For patients of Asian ancestry or indigenous peoples of the Americas: Target maintenance doses of 75-300 mg/day depending on metabolic capacity (lower with obesity or valproate co-prescription). 2
- For patients of European/Western Asian ancestry: Target maintenance doses of 100-400 mg/day depending on metabolic factors. 2
- For other ancestries in the US: Target maintenance doses of 150-600 mg/day depending on metabolic capacity. 2
- Measure clozapine blood levels on day 8 to estimate individual metabolism capacity and adjust titration speed accordingly. 2
Special Considerations for Early Psychosis
Use exceptionally slow titration in patients within their first year of psychosis, as they may achieve sustained response at remarkably low maintenance doses (mean 81 mg/day in one study) compared to those with longer illness duration. 4
Maintenance Dosing
Target Dose Range
- Standard maintenance range is 300-600 mg/day in the United States for most patients. 5, 2
- Titrate based on therapeutic response and tolerability, aiming for plasma levels of at least 350 ng/mL if therapeutic response is not achieved at lower concentrations. 5
Plasma Level Monitoring
Target plasma concentrations of 350-550 ng/mL for optimal therapeutic response:
- If positive symptoms persist after 12 weeks at therapeutic plasma concentration (≥350 ng/mL), consider increasing dose to achieve plasma levels up to 550 ng/mL. 5
- Plasma concentrations above 550 ng/mL have diminishing returns (number needed to treat = 17) and increased seizure risk; use only after consultation with patient/carers and consider prophylactic lamotrigine. 5
- Measure clozapine levels: annually, with smoking pattern changes, during infection/inflammation, with mental state changes, with new adverse effects, or when CYP1A2 inhibitors are added. 6
Metabolic Considerations
- Female non-smokers require the lowest doses; male smokers require the highest doses due to CYP1A2 metabolism differences. 2
- Co-prescription of CYP1A2 inhibitors (oral contraceptives, valproate), obesity, or inflammation with elevated C-reactive protein creates poor metabolizer status requiring dose reduction. 2
Monitoring Requirements
Absolute Neutrophil Count (ANC) Monitoring
Baseline ANC must be ≥1500/μL for general population or ≥1000/μL for documented Benign Ethnic Neutropenia before initiating clozapine. 1
ANC monitoring schedule:
- Weekly ANC for the first 18 weeks of treatment. 6
- Every 4 weeks from week 18 through 2 years of continuous treatment. 6
- Discontinue routine ANC monitoring after 2 years of stable treatment, as 85% of expert consensus supports this approach. 6
- Annual complete blood count should continue after cessation of ANC monitoring to screen for hematological malignancies. 6
Critical safety point: The risk of neutropenia-related hospitalization is highest in the first 6 months (incidence rate 2.21 per 1000 person-years), with a 12-fold increased risk compared to olanzapine. 7
C-Reactive Protein (CRP) Monitoring
Measure CRP at baseline and weekly for at least the first 4 weeks to identify inflammation, including clozapine-induced inflammation from rapid titration. 2, 3
Adverse Drug Reaction (ADR) Monitoring
Monitor systematically for the following ADRs at each ANC testing appointment for the first 2 years, then every 3 months after ANC monitoring ceases: 6
- Weight gain/metabolic syndrome
- Constipation and gastrointestinal hypomotility
- Gastroesophageal reflux
- Sialorrhea
- Sedation
- Nocturnal enuresis/urinary incontinence
- Dizziness/orthostatic hypotension
- Tachycardia
- Sleep apnea
- Obsessive-compulsive symptoms
- Seizures/myoclonus
- Pneumonia
Use a standardized ADR monitoring checklist, endorsed by 93% of international experts. 6
Cardiac Monitoring
Maintain high suspicion for myocarditis and cardiomyopathy, which can be fatal:
- Discontinue clozapine immediately if chest pain, tachycardia, palpitations, dyspnea, fever, flu-like symptoms, hypotension, or ECG changes occur. 1
- Obtain cardiac evaluation upon suspicion; generally do not rechallenge patients with clozapine-related myocarditis or cardiomyopathy. 1
Follow-Up Schedule
After 2 years of stable treatment:
- Primary care visits every 3 months for ADR screening in shared-care models. 6
- Psychiatric prescriber visits every 6-12 months in shared-care models, or every 3 months if patient only sees psychiatrist. 6
Critical Safety Warnings
Seizure Risk
- Risk is dose-related; use caution in patients with seizure history, CNS pathology, medications lowering seizure threshold, or alcohol abuse. 1
- Caution patients about activities where sudden loss of consciousness could cause serious harm. 1
Cardiovascular Risk During Titration
- Orthostatic hypotension, bradycardia, syncope, and cardiac arrest can occur with first dose or doses as low as 12.5 mg/day, or when restarting after brief interruption. 1
- Use cautiously in patients with cardiovascular/cerebrovascular disease or conditions predisposing to hypotension (dehydration, antihypertensive medications). 1
Infection Reporting
Advise patients to immediately report symptoms of severe neutropenia or infection (fever, weakness, lethargy, sore throat). 1
Metabolic Protection
Offer metformin concomitantly with clozapine to attenuate weight gain; assess renal function before starting and avoid in renal failure. 5